Group 1 - The core viewpoint of the articles highlights the performance and financial metrics of He Shi Eye Hospital Group, indicating a recent stock price increase and a decline in shareholder numbers [1][2] - As of May 16, the closing stock price of He Shi Eye Hospital was 20.78 yuan, up by 1.02%, with a latest price-to-book ratio of 1.72, marking a new low in 13 days and a total market capitalization of 3.284 billion yuan [1] - The company reported a revenue of 291 million yuan for Q1 2025, representing a year-on-year increase of 2.35%, and a net profit of 32.53 million yuan, which is a 12.27% increase year-on-year, with a gross profit margin of 43.80% [1] Group 2 - The company has 9,399 shareholders as of March 31, 2025, a decrease of 392 shareholders from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - He Shi Eye Hospital's main business focuses on personalized and intelligent eye health management services, including refractive surgery, cataract treatment, retinal disease treatment, and other eye disease treatments [1] - The company's price-to-earnings (P/E) ratio is significantly lower than the industry average, with a trailing P/E of -137.73 compared to the industry average of 37.33 [2]

普瑞眼科2025年第一季度报告显示，普瑞眼科报告期内营业总收入为7.42亿元，同比增长9.82%；归属 于上市公司股东的净利润为2727.94万元，同比增长61.18%；归属于上市公司股东的扣除非经常性损益 的净利润为2831.55万元，同比增长48.37%；经营活动产生的现金流量净额为1.95亿元。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | (%) | | | 营业收入(元) | 742. 251. 316. 24 | 675,882,973,16 | | 9.82% | | 归属于上市公司股东的净利 | 27, 279, 356. 63 | 16, 924, 936, 43 | | 61. 18% | | 润(元) | | | | | | 归属于上市公司股东的扣除 非经常性损益的净利润 | 28, 315, 487, 26 | 19,084,077.60 | | 48. 37% | | (元) | | | | | | 经营活动产生的现金流量净 额(元) | 194. 676. 885. 40 | 12 ...

接到举报后，南通市纪委监委组成了工作专班，对相关问题进 行了全面彻查。目前，已依规依纪对有关涉事人员进行了严格 处理。 作者：张铃 封图：图虫创意 同时，艾芬亦对爱尔眼科员工提起过诉讼。艾芬曾起诉爱尔眼科职工段某民、刘某菲、刘某等侵犯 名誉权，2025年4月，武汉市江汉区人民法院一审判决艾芬胜诉 。 在该一审判决前后 ，艾芬的 微博账号"急诊向日葵艾芬"被封。 南通爱尔眼科医院是爱尔眼科（300015.SZ）旗下医院。爱尔眼科成立于2003年，是中国眼科龙 头，截至2024年底，爱尔眼科在全球范围内共有974家品牌医院、眼科中心及诊所，其中811家 在中国内地。此前，爱尔眼科董事长陈邦曾于2022年初发内部信，称将全面拥抱社会监督。 艾芬曾在抗击新冠疫情中作出积极贡献，民间评价其为"疫情发哨人"。2020年5月，艾芬因白内 障在武汉爱尔眼科医院进行了人工晶体植入手术，术后5个月出现右眼视网膜脱落，12月其申诉右 眼几乎失明，质疑医院存在违规操作。爱尔眼科则称，艾芬视网膜脱离与医院手术没有直接关联。 有关部门曾就该事件成立调查组，爱尔眼科称，艾芬不同意进行医疗鉴定、不走法律程序。 艾芬多次在社交平台质疑爱尔眼科 ...

Group 1 - On May 15, 2023, the CEO of Nantong Aier Eye Hospital, Yu Wenjuan, was given a disciplinary sanction by the Nantong Municipal Commission for Discipline Inspection, and her status as a member of the Political Consultative Conference was revoked [1] - The disciplinary action followed a report submitted by Ai Fen, the director of the emergency department at Wuhan Central Hospital, alleging that several public officials in Nantong accepted invitations to banquets hosted by Yu Wenjuan [1] - The Nantong Municipal Commission for Discipline Inspection formed a special task force to investigate the allegations, leading to strict disciplinary actions against the involved personnel [1] Group 2 - Aier Eye Hospital, part of Aier Eye Group (300015.SZ), is a leading eye care provider in China, with 974 hospitals and clinics globally, including 811 in mainland China as of the end of 2024 [2] - Ai Fen, known for her contributions during the COVID-19 pandemic, has raised concerns about the management and treatment practices at Aier Eye Hospital, particularly regarding her own medical experience [2] - Legal disputes have arisen between Ai Fen and Aier Eye employees, with multiple lawsuits filed over defamation, resulting in mixed outcomes in court [3]

投资者关系活动记录表 编号：2025-003 | | □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 | | --- | --- | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称及人员 | 通过全景网"投资者关系互动平台"（https://ir.p5w.net）参与 | | 姓名 | 厦门辖区上市公司 2024 年年报业绩说明会暨投资者网上集体 | | | 接待日活动的投资者 | | 时间 | 2025 年 5 月 15 日（周四）下午 15:40~17:00 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 陈凤国先生 董事 | | | 陈鹭燕女士 财务总监 | | 上市公司接待人员 姓名 | 曹乃恩先生 董事会秘书 | | | 王志强先生 独立董事 | | | 赵 冀先生 保荐代表人 | | | 1、请问一下 年公司，持续发展和业务开展做了哪些调 25 | | | 整和创新？ | | | 尊敬的投资者您好，感谢您对华厦眼科的关注。从 2025 | | | 年起，公司将按照《华 ...

中证报中证网讯(王珞)日前，2025未来医疗医药100强展会在苏州举行，何氏眼科（301103）受邀参 加。何氏数字医疗首席科学家、辽宁何氏医学院视觉智能中心主任何星儒在演讲时表示，近年来，何氏 眼科围绕全球眼健康总体方向，以构建"智慧光明城"为战略目标，依托眼健康全产业链生态平台优势， 借助大数据、人工智能、基因、干细胞等新技术，通过精准医疗和智慧医疗赋能，为患者提供数字化、 全方位、全场景、全生命周期的眼健康管理服务新模式，持续提升基层眼科医疗服务能力。 何星儒分享了何氏眼科通过大数据和人工智能等新技术赋能近视防控、糖尿病眼病防治及社区防盲公共 卫生模式搭建的成果与经验，充分落地应用数字化技术，推动其在眼科公共卫生领域中发挥更大价值。 近年来，何氏眼科将数字技术、人工智能与公益相结合，将专业医疗技术和百姓需求相结合，持续搭建 布局广泛的基层眼科医疗服务网络，加快推进"何氏智慧眼健康管理站"和"光明小屋"建设，以眼科智能 设备为入口，通过AI智能诊断，结合专家线上看诊，实现了眼部疾病和慢性疾病早监测、早预警、早 干预、早治疗，真正让数据多跑路、群众少跑腿，打通基层眼保健的"最后一公里"，有力提升了眼健康 公 ...

5月13日，辽宁省委省政府对在2024年辽宁全面振兴新突破三年行动攻坚之年作出突出贡献的241户企业予以 通报表扬，何氏眼科（301103）连续第二年荣获此殊荣。 2024年以来，扎根辽宁30年的何氏眼科以科技创新蓄势赋能，增强发展实力，提升服务能力，推动眼健康服 务向智能化、精准化和普惠化转型，助力健康辽宁和数字辽宁建设。 何氏眼科围绕"健康中国"战略和全球眼健康总体方向，以构建"智慧光明城"为战略目标，发挥独有的眼健康 全产业链生态平台优势，借助大数据、人工智能、基因、干细胞等新技术，通过精准医疗和智慧医疗赋能， 加快发展新质生产力，全面开启数字化、全方位、全场景、全生命周期眼健康管理的服务新模式，不断满足 人民群众多层次多样化眼健康和大健康需求。 为切实提高儿童青少年视力健康水平，作为辽宁省青少年近视防控基地，何氏眼科通过科技创新和模式探 索，构建了辽宁特色的"365近视防控体系"。 此外，何氏眼科将数字技术、人工智能与公益相结合，专业医疗技术和百姓需求相结合，持续在辽宁全省范 围内搭建布局广泛的基层眼科医疗服务网络。公司实施的"光明小屋"项目在2024年全国首届社会办医"新质生 产力"案例大赛中荣膺服 ...

Core Viewpoint - The recent removal of Hema Medical from the Hong Kong Stock Connect list has led to significant stock price declines, with a notable drop of 26.92% over the month following the adjustment [1][4]. Company Performance - Hema Medical's stock price fell sharply after being removed from the Hong Kong Stock Connect list, with a 16.25% drop on April 7, reaching a new low of 1.33 HKD [1]. - The company experienced a total of 35 share buybacks in 2023, with 15 occurring in April alone, amounting to 10.81 million shares, or 0.86% of total share capital [4][7]. - Despite the stock price recovery after April 7, trading volume has significantly decreased, indicating low investor interest [7]. Financial Results - For the fiscal year 2024, Hema Medical reported revenues of 1.913 billion HKD, a decrease of 0.56% year-on-year, and a loss attributable to shareholders of 135 million HKD, compared to a profit of 61.99 million HKD in the previous year [7][10]. - The decline in revenue was attributed to a significant drop in sales of COVID-related medical supplies, which fell from 19.43 million HKD to zero [7][12]. Industry Context - The overall ophthalmology market in China has been growing, with expectations of reaching 252.15 billion HKD by 2025, but the sector is facing structural challenges leading to a slowdown in growth [11]. - Major players in the ophthalmology sector, including Hema Medical, are experiencing revenue declines, with Hema's eye care revenue in key cities like Beijing and Shanghai dropping by 2.8% and 16.1%, respectively [12]. - The competitive landscape in the ophthalmology sector has intensified, leading to significant challenges for both private and public hospitals, resulting in a risk of goodwill impairment and reduced profitability [12].

今春一个清晨，在安徽省长丰县下塘中心卫生院，人们在一台移动眼科诊疗车前排起长队。当天，中古友谊眼科医院的中国和古巴医生们为群 众进行义诊。 十多年来，从城市到农村、从水乡到山区，这些医生累计开展不下百余场义诊，足迹遍布安徽全省。 身边的"佩医生" 2011年，随着第一批古巴专家到来，中古友谊眼科中心（中古友谊眼科医院前身）在安徽省第二人民医院正式开诊。至今，这里已迎来5批共 29名古巴眼科专家。 从"师生情"到"同事缘" "从第一批专家抵达、第一批设备入关开始，中古双方通力合作，共同攻克一道道难关。"安徽省第二人民医院前院长张兵回忆道，项目初期， 中国医护人员为古巴专家当翻译、提供生活帮助，古巴专家则调试设备、手把手传授技术，双方结下深厚情谊。 古巴卫生部长何塞·安赫尔·波塔尔·米兰达高度评价中古友谊眼科医院合作项目。他说，未来双方还将在生物医药、临床研究、人工智能等领域 深化合作，造福两国人民。 在中古友谊眼科医院，古巴二级眼科专家（该国最高级）、小儿眼科能手佩德罗·卡斯特罗被中国同事和朋友亲切称为"佩医生"。他到安徽已 有四年。 "佩医生"是小患者们的"大朋友"。他的诊室里，一个在母亲怀里的小女孩显得有些 ...

Core Viewpoint - The introduction of the minimally invasive all-laser precise 4.0-VISULYZE technology by Suqian Aier Eye Hospital marks a significant advancement in the refractive surgery field, responding to the increasing demand for safety, precision, and personalization in myopia correction surgeries [1][13]. Group 1: Technological Advancements - The development of refractive surgery has reached multiple milestones, with the introduction of the all-laser SMILE technology representing the 3.0 era, and the new 4.0-VISULYZE technology being a comprehensive upgrade focused on intelligent and personalized care [1][4]. - The 4.0-VISULYZE technology features four core innovations: visualized surgical results, full-process variable control, personalized Nomogram analysis system, and a closed-loop patient management system, ensuring precise control throughout the surgical process [4][6]. Group 2: Precision and Safety Enhancements - The technology utilizes big data algorithms to analyze various patient-specific metrics, allowing for customized surgical plans that move away from traditional one-size-fits-all approaches [6]. - Full environmental, process, and variable management significantly reduces postoperative refractive errors and lowers the risk of complications such as dry eyes and glare, providing a more stable and safer postoperative experience [8]. - Compared to traditional laser and semi-laser technologies, the 4.0 technology reduces the corneal cutting area by approximately 45%, preserving corneal nerve integrity and enhancing postoperative visual quality, leading to quicker recovery and a more comfortable visual experience [11].